BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Abbott launches Next-Gen FreeStyle LibreÂ® 2 Plus in India

21 August 2025 | News

Abbottâ??s latest innovation in the Continuous Glucose Monitoring portfolio



Abbott, the global healthcare company, has announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott's latest addition to the FreeStyle Libre sensor portfolio. The launch took place at an event in Mumbai.

This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible smartphone when low glucose levels or high glucose levels happen, letting them make informed decisions.

With 101 million people living with diabetes, India is home to the second-largest diabetes population in the world. This staggering number highlights the urgent need for accessible, real-time tools like continuous glucose monitors (CGMs) to help people manage their diabetes confidently and proactively. Glucose monitoring, alongside appropriate therapy, is key to managing the condition and preventing complications.

"Abbott's pioneering FreeStyle Libre technology is transforming the way diabetes is managed for over seven million individuals across the globe. We are thrilled to introduce this life-changing innovation to India, where it holds immense potential to empower people to be able to manage the condition better," said Dr Kenneth Lee, Regional Medical Affairs Director, Asia Pacific, Diabetes Division, Abbott. "FreeStyle Libre2 Plus performance meets robust accuracy standards to ensure reliable glucose readings for all intended patient populations and glycemic ranges. It gives people the freedom to monitor their glucose levels without routine fingersticks, helping them make more informed decisions."

Studies show that FreeStyle Libre technology can help reduce low blood sugar episodes by up to 43%, a 0.9% to 1.5% drop in HbA1c levels, and even cut hospital visits by 66%. Libre technology has been shown to reduce cardiovascular complication risk by 78% in people with Type 1 diabetes post-severe hypoglycemia, and lower hospitalisation risk for stroke and diabetes-related complications by 44% in insulin-treated Type 2 diabetes. And for caregivers, real-time alerts offer peace of mind and the chance to act before situations get serious.